DCGI Approves Emergency Use Of Drug Developed By DRDO Lab For Treatment Of Moderate To Severe COVID-19 Patients

In a development that can ease the shortage of medical oxygen and hospital beds, the Drugs Controller General of India (DCGI) has approved an anti Covid-19 drug for emergency use in moderate to severe Covid-19 patients.

A therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion. The drug will be of immense benefit to the people suffering from Covid-19, the Ministry of Defence said in a statement.

The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

In the ongoing second Covid-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of Covid-19 patients.